Abstract
IntroductionThe aim of this study was to evaluate the variability of 18F-FDG liver uptake at interim PET/CT among patients with high-grade lymphomas. MethodsForty-six patients with diffuse large B-cell lymphomas (DLBCL) who underwent 18F-FDG PET/CT at baseline (PET1) and after a few cycles of therapy (PET2) were included retrospectively. SUV mean normalized for body weight (SUVmean) and for lean body mass (SULmean) were obtained from 2-dimensional regions of interest (ROI) in the right lobe of the liver. ResultsLiver SUVmean values for the 46 patients were not different before and after the courses of chemotherapy. On univariate and multivariate analysis, liver SUVmean values increased with BMI (P=0.0031). No significant correlation was found between delay post-injection, blood glucose level, age, gender and liver SUVmean. We found no statistically significant correlation between the liver SULmean or mediastinum SUVmean and studied variables. No factors affecting intrapatient hepatic uptake variation between PET1 and PET2 were found on correlation analysis. ConclusionAt interim PET in diffuse large B-cell lymphomas, liver SUVmean depends on BMI, but not liver SULmean. Caution is required when using liver SUV as reference in patients with high BMI.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
